An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
EBioMedicine(2019)
摘要
Our study supports the importance of accurate patient stratification and rational drug combinations to gain benefit from MEK inhibition in patients with KRAS mutant NSCLC. We develop a genotype-based strategy that identifies CK2 as a promising co-target in KRAS(G12C) mutant NSCLC by using available pharmacogenomics gene expression datasets. This approach is applicable to other oncogene driven cancers. FUND: This work was supported by grants from the National Natural Science Foundation of China, the National Key Research and Development Program of China, the Lung Cancer Research Foundation and a Mildred-Scheel postdoctoral fellowship from the German Cancer Aid Foundation.
更多查看译文
关键词
Pharmacogenomic profiles,KRAS mutations,Lung adenocarcinoma,CSNK2A1,CK2,MEK inhibitor,Silmitasertib,Wnt/β-catenin,EMT
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要